- End of the line for MSD's TIGIT, LAG-3 cancer drugs
MSD has decided to abandon the development of its anti-TIGIT antibody
vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in...
from: Pharmaphorum
|
- Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs
Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose
Combinations with Pembrolizumab
Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the discontinuation of the clinical development...
from: Business Wire
|
- Merck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosion
After multiple clinical failures, it's finally the end of the road for
Merck's TIGIT program. The company is dropping development of its...
from: Endpoints News
|
- Spotlight On: Merck & Co. scraps TIGIT, LAG-3 lifecycle strategies for
flagship drug Keytruda
As a result, focus has sharpened on a subcutaneous version of Keytruda and
Merck's newly in-licensed PD-1/VEGF bispecific.
from: FirstWord Pharma
|
- Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3,
both of which were in the middle of Phase 3 testing.
from: BioPharma Dive
|
- Merck & Co. Calls Time On Flop TIGIT And LAG-3 Programs
Once a key part of its next-generation plans in cancer, Merck & Co. has
called a halt to the last remaining Phase III studies of its TIGIT-...
from: insights.citeline.com
|
- Merck (MRK) Halts Development of TIGIT and LAG-3 Antibodies
Merck (MRK) has announced the termination of the development of its TIGIT
antibody, Vibostolimab (MK-7684), and LAG-3 antibody,...
from: GuruFocus
|
- Merck Discontinues KeyVibe & KEYFORM Clinical Development Programs
Vibostolimab and favezelimab were being studied in combination with
pembrolizumab (Keytruda) for various types of cancer.
from: Contract Pharma
|
- Merck discontinues development of 2 experimental cancer drugs after trial
failures
Merck said on Monday it has discontinued the development of two
experimental cancer drugs after their failure in several trials.
from: Reuters
|
